Is Ruby Cardin on the market? What is the price?

Lurbinectedin (Lurbinectedin), this innovative drug, has been successfully launched and used in many countries and regions around the world. Its research and development process has undergone rigorous scientific verification and clinical trials to ensure its efficacy and safety for patients with small cell lung cancer. In particular, rubicatin has demonstrated significant efficacy in the treatment of metastatic small cell lung cancer that has progressed after platinum-based chemotherapy.

On June 15, 2020, the U.S. Food and Drug Administration (FDA) approved the marketing application for rubicatin, opening the door to its application in the treatment of small cell lung cancer. The drug was subsequently approved in several countries, reflecting widespread recognition of its efficacy by the international medical community. It is worth mentioning that rubicatin has also been included in multiple authoritative cancer treatment guidelines, including the ESMO Small Cell Lung Cancer Guidelines and the NCCN Small Cell Lung Cancer Guidelines, further proving its important position in the field of lung cancer treatment.

Rubicardin is not currently on the market in China, but patients can purchase it through foreign channels or consult professional overseas medical companies. The only version currently on the market is the original research version, manufactured by PharmaMar, a Spanish biopharmaceutical company. This version is available in Singapore and the United States. Each box of 4 mg is priced at 91,000 yuan in the US market, but it is more economical in Singapore, with only 34,000 yuan per box. If the patient has more questions about Rubicatin, please consult a regular overseas medical consulting company.

In general, rubicatin, as a new anti-cancer drug, has been successfully launched and used globally, providing new treatment options for patients with small cell lung cancer and bringing more survival opportunities and hope.